Literature DB >> 24225216

[Clinical significance of dynamic monitoring of procalcitonin in guiding the use of antibiotics in patients with sepsis in ICU].

Bao-hua Liu1, Hai-feng Li, Yu Lei, Shi-xing Zhao, Ming-li Sun.   

Abstract

OBJECTIVE: To investigate the significance of dynamic monitoring of procalcitonin (PCT) in guiding the use of antibiotics for treating patients with sepsis in intensive care unit (ICU).
METHODS: Eighty-two patients with sepsis from January 2012 to June 2013 hospitalized in ICU of First Hospital of Jilin University were enrolled, and they were randomly divided into regular antibiotic therapy group (RAT group, n=40) and PCT monitoring in guiding the use of antibiotics group (PCT group, n=42). Patients in RAT group were treated according to principle of antibiotics usage, while in PCT group patients' PCT value was observed everyday. When no active symptoms of infection were shown, and acute physiology and chronic health evaluation II (APACHEII) scores declined, PCT value decreased over 90% or PCT value lower than 0.25 μg/L time point were selected as drug withdrawal indication. The general status of the patient, antimicrobial drug use time, and prognosis were compared between the two groups, and Kaplan-Meier method was used for survival curve analysis. Variance analysis was used for repeating measurement to observe dynamic serum PCT level of the two groups of patients for survival and death during 7 days.
RESULTS: Mann-Whitney U test or χ(2) test showed that there were no statistical significance in age, gender, APACHEII score, blood culture positive rate, sputum culture positive rate, cardiac insufficiency, renal failure, respiratory failure, and ventilator and hemofiltration usage (all P>0.05). Log Rank test results showed that the time of antimicrobial drug usage was significantly reduced in PCT group than that in RAT group [days: 8.1±0.3, 95% confidence interval (95%CI 8.3-9.7) vs. 9.3±0.3 (95%CI 8.7-10.1), P=0.013]. Kaplan-Meier univariate survival curves showed that the speed of curve declination in PCT group was faster significantly than that in RAT group, suggesting that the time of using antimicrobial drug was shortened. There was no significant difference in length of hospital stay, ICU stay time, number of death in 28 days, number of cases of recurrence in 28 days and clinical cure rate between two groups (all P>0.05). PCT level in non-survivors in both groups was significantly higher than that in the survivors, exceeding more than 10 μg/L in the early and late stages of treatment.
CONCLUSIONS: Dynamic monitoring of PCT can effectively reduce antimicrobial drug use in ICU patients with sepsis, but there is no significant difference in patients' prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24225216     DOI: 10.3760/cma.j.issn.2095-4352.2013.11.013

Source DB:  PubMed          Journal:  Zhonghua Wei Zhong Bing Ji Jiu Yi Xue


  7 in total

Review 1.  Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Authors:  Brenda Ng Andriolo; Regis B Andriolo; Reinaldo Salomão; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2017-01-18

2.  Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis.

Authors:  Dominique J Pepper; Junfeng Sun; Chanu Rhee; Judith Welsh; John H Powers; Robert L Danner; Sameer S Kadri
Journal:  Chest       Date:  2019-02-14       Impact factor: 9.410

Review 3.  Interventions to improve antibiotic prescribing practices for hospital inpatients.

Authors:  Peter Davey; Charis A Marwick; Claire L Scott; Esmita Charani; Kirsty McNeil; Erwin Brown; Ian M Gould; Craig R Ramsay; Susan Michie
Journal:  Cochrane Database Syst Rev       Date:  2017-02-09

4.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.

Authors:  Laura Evans; Andrew Rhodes; Waleed Alhazzani; Massimo Antonelli; Craig M Coopersmith; Craig French; Flávia R Machado; Lauralyn Mcintyre; Marlies Ostermann; Hallie C Prescott; Christa Schorr; Steven Simpson; W Joost Wiersinga; Fayez Alshamsi; Derek C Angus; Yaseen Arabi; Luciano Azevedo; Richard Beale; Gregory Beilman; Emilie Belley-Cote; Lisa Burry; Maurizio Cecconi; John Centofanti; Angel Coz Yataco; Jan De Waele; R Phillip Dellinger; Kent Doi; Bin Du; Elisa Estenssoro; Ricard Ferrer; Charles Gomersall; Carol Hodgson; Morten Hylander Møller; Theodore Iwashyna; Shevin Jacob; Ruth Kleinpell; Michael Klompas; Younsuck Koh; Anand Kumar; Arthur Kwizera; Suzana Lobo; Henry Masur; Steven McGloughlin; Sangeeta Mehta; Yatin Mehta; Mervyn Mer; Mark Nunnally; Simon Oczkowski; Tiffany Osborn; Elizabeth Papathanassoglou; Anders Perner; Michael Puskarich; Jason Roberts; William Schweickert; Maureen Seckel; Jonathan Sevransky; Charles L Sprung; Tobias Welte; Janice Zimmerman; Mitchell Levy
Journal:  Intensive Care Med       Date:  2021-10-02       Impact factor: 17.440

5.  Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis.

Authors:  Tao Zhang; Yan Wang; Qianting Yang; Yalin Dong
Journal:  BMC Infect Dis       Date:  2017-07-24       Impact factor: 3.090

6.  Predictive Value of Immune Cell Subsets for Mortality Risk in Patients With Sepsis.

Authors:  Ying Zhang; Jia Wang; Le Hu; Jingchao Xuan; Yifan Qu; Yixuan Li; Xinghua Ye; Long Yang; Jun Yang; Xiangqun Zhang; Junyu Wang; Bing Wei
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

7.  A behavioural approach to specifying interventions: what insights can be gained for the reporting and implementation of interventions to reduce antibiotic use in hospitals?

Authors:  Eilidh M Duncan; Esmita Charani; Janet E Clarkson; Jill J Francis; Katie Gillies; Jeremy M Grimshaw; Winfried V Kern; Fabiana Lorencatto; Charis A Marwick; Jo McEwen; Ralph Möhler; Andrew M Morris; Craig R Ramsay; Susan Rogers Van Katwyk; Magdalena Rzewuska; Brita Skodvin; Ingrid Smith; Kathryn N Suh; Peter G Davey
Journal:  J Antimicrob Chemother       Date:  2020-05-01       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.